DOCSLIB.ORG

SARS-Cov-2 Report 12 June 2020 Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SARS-Cov-2 Report 12 June 2020 Contents José Luis Pires SARS-Cov-2 Report 12 June 2020 Contents SARS-Cov-2 ➢ Confirmed cases by Country ➢ Deaths by Country ➢ Total confirmed Covid-19 cases and deaths per million people ➢ Daily new confirmed Covid-19 cases and deaths per million people (new) ➢ Covid-19 Projections – Portugal (new) ➢ Portugal, Lisbon, Loures, Macau, New Jersey, Cork - Cases by day and Total ➢ Reported infections per 1 million people for select countries with over 100 reported cases ➢ New cases vs 7-day average ➢ Cases Curve Simulator ➢ The latest coronavirus updates and developments impacting the global pharmaceutical supply chain June 2020 Confidential Hovione © 2020 2 Coronavirus (SARS-CoV-2 / Covid-19) – Confirmed cases by country Note: Selected Countries, sorted by # of cases US 2,023,347 Brazil 802,828 Russia 510,761 India 297,535 UK 292,860 Spain 242,707 Italy 236,142 France 192,493 Germany 186,691 Turkey 174,023 Canada 99,159 China 84,217 Belgium 59,711 Netherlands 48,458 Sweden 48,288 12 June 2020 5 June 2020 29 May 2020 22 May 2020 15 May 2020 8 May 2020 1 May 2020 24 April 2020 Singapore 39,850 Portugal 35,910 Switzerland 31,044 Argentina 27,373 Ireland 25,238 Philippines 24,175 Israel 18,701 Japan 17,230 Austria 17,034 Denmark 12,235 Korea 12,003 Norway 8,608 Morocco 8,537 Malaysia 8,369 Australia 7,289 Finland 7,064 Hungary 4,053 Last Updated at 12 June 2020, 9:33 AM Luxembourg 4,052 Thailand 3,129 by the Center for Systems Science and Engineering Greece 3,088 at Johns Hopkins University Croatia 2,249 https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 Estonia 1,970 : Iceland 1,807 Lithuania 1,756 Source Slovenia 1,490 June 2020 Confidential Hovione © 2020 3 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 Coronavirus (SARS-CoV-2 / Covid-19) – Deaths by Country Note: Selected Countries, sorted by # of cases 120,000 113,820 100,000 80,000 60,000 Last Updated at 12 June 2020, 9:33 AM by the Center for Systems Science and Engineering 40,919 41,364 at Johns Hopkins University 40,000 34,167 29,349 27,136 20,000 8,772 9,636 6,7058,498 8,071 4,763 4,638 6,0634,814 25 1,5041,9377651,7031,036300 922 674 593 277 242 211 118 102 325 555 110 58 183 106 69 10 74 109 0 Source: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 June 2020 Confidential Hovione © 2020 4 Total confirmed Covid-19 cases per million people June 2020 Confidential Hovione © 2020 5 Daily new confirmed Covid-19 cases per million people Portugal ranks as EU country with second highest number of new cases in last 14 days, per million people June 2020 Confidential Hovione © 2020 6 Total confirmed Covid-19 deaths per million people June 2020 Confidential Hovione © 2020 7 Daily new confirmed Covid-19 deaths per million people June 2020 Confidential Hovione © 2020 8 Covid-19 Projections – Portugal - Cases June 2020 Confidential Hovione © 2020 9 Source: https://covid19-projections.com/portugal Covid-19 Projections – Portugal - Deaths June 2020 Confidential Hovione © 2020 10 Source: https://covid19-projections.com/portugal Coronavirus (SARS-CoV-2 / COVID 19) – Portugal - Confirmed cases by day 1600 1516 1400 1200 1035 1000 902 852 808 815 792 783 754 750 800 724 712699 663657 633 638 643 598 603 595 549 540 553 600 515 514 521516 533 472 480 460 446 452 444 421 371 366377382 400 349 350 342 320 331 310 302 295 306 288 285304 297 294 260 264 252271 257 270 235 242 234 227226 228 219 223 219 200 194 181 183 178 175138 187 173 195 192 143 163 152165 200 117 7686 92 98 3457 2 2 2 3 4 8 9 9 21819 0 0 * Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ * - recalculated numbers June 2020 Confidential Hovione © 2020 11 Coronavirus (SARS-CoV-2 / COVID 19) – Portugal - Total cases by day 40000 120% 36,180 33,969 35,910 35,30635,600 34,69334,885 31,946 34,351 35000 100% 33,26133,592 32,70032,895 30,200 32,20332,500 31,596 100% 31,00731,292 30,47130,62330,788 29,43229,66029,912 30000 28,81029,03629,209 27,91328,13228,31928,583 27,26827,40627,58127,679 26,715 25,70226,182 25,05625,35125,19025,28225,524 80% 24,02724,32224,505 25000 23,39223,864 22,797 21,98222,353 21,379 62% 20,863 20,206 19,685 20000 18,84119,022 60% 18,091 51% 17,448 50%50% 16,58516,934 15,987 45% 15,472 44%43% 44%44% 43% 15000 13,956 13,141 35%35% 30% 12,452 40% 32% 25% 11,27811,730 10,524 30% 29% 9,886 27% 9,034 10000 25% 8,251 22% 20%21% 7,443 18% 5,9626,40816% 15% 5,17015% 20% 4,268 5000 3,544 11%9%9% 11% 2,995 7% 6%7% 6% 6% 5% 2,0602,362 4% 6% 4% 1,2801,600 3%4% 3%4% 3%3%3%2%3% 3% 2% 6427851,020 2% 1% 2%2% 2%1%1%1% 1% 1%1%2%2%2%1%1% 1%1%1%1%1%1%1%1%1%1%1%1%0%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1% 0%2 4 6 9 13213039415978112169245331448 0% 0% 0 0% # of cases % increase Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ June 2020 Confidential Hovione © 2020 12 Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – Hospital: Stable vs ICU 1400 13021284 1253 1227 1243 1211 1200 1208 118011731179117511771187 1172 1200 1146 1099 1095 10751084 1068 10421058 1040 1005995 980968 1000 936 892 874 855856 838 842 818 813 815797805 800 726 709 692680 673657649 628629 627 609608 571 576 550 600 536531 529 513510512 514 440 486 474471 445 418 432428 421414 417415 398 394 400 354 366 276 267270271 245251 245 230240 241226233228 229222228224 206 201203 218208 215213207204 191 188 188 188186182176172 172 156169 164 169 154150 200 139139 126 136 144143134136135127 73 107107114 120112112113 108 115108105 8989 89 103 112 101939284 616171 80787271666566636464 657070 4057 414748 58565858575855 213038 20202635 0 0 0 0 09 130 0 0 0 0 0 0 0 10 9 1817 0 Hospital Stable Hospital ICU Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ June 2020 Confidential Hovione © 2020 13 Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – Deaths vs Recoveries 25000 22200 2174222002 2052621339 208072099521156 2007920323 189111955219869 1918619409 20000 18637 1809618349 1754917822 15000 10000 75907705 6430643164526452 4636 5000 3822 3013318231983328 249925492549 1505 207622582422 1289 1383 1465 1470151916471671168917121743 14471455147414791485149214971504 1146120112281277132913571389 10891105111411261135114411631175118411901203121812311247126312771302131613301342135613691396141014241436 73576291778582085488090392894897398910071023104310631074 380409435470504535567383599493629519657610687610714610 0 0 0 0 0 0 0 0 0 0 0 01 01 01 02 13 13 23 3 56 125 145 14232233224343604376100431194314043160431874320968246682667529575140311184345196205233266277277347 0 Total Confirmed Deaths Total Confirmed Recoveries Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ June 2020 Confidential Hovione © 2020 14 Coronavirus (SARS-CoV-2 / COVID 19) Portugal 12June 020 June 2020 Confidential Hovione © 2020 15 Coronavirus (SARS-CoV-2 / COVID 19) – Loures - Confirmed cases by day 60 56 54 52 50 48 43 40 40 37 35 33 33 34 33 32 31 31 31 30 29 29 30 27 27 25 25 23 2323 22 21 21 20 19 18 20 17 17 17 17 15 14 13 12 12 11 11 11 11 10 10 9 9 9 9 9 8 8 8 8 8 8 10 7 7 7 6 5 5 4 4 4 3 3 2 2 2 1 1 0 0 0 0 0 0 0 1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr 1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may 01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun 10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar 10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ June 2020 Confidential Hovione © 2020 16 Coronavirus (SARS-CoV-2 / COVID 19) – Loures - Total cases by day 1600 120% 1,383 104% 1,352 1400 1,331 1,288 100% 1,172 1,236 1,209 1,191 1200 1,147 1,114 1,089 1,066 982 1,043 1,009 80% 1000 934 894 863 828 802819 800 771 60% 715 678 642656 612 591604 559576 600 536 497505507 40% 453464464 408410420 386393400 400 369 315315315 20% 292292301303304 251257260 17% 17% 17% 221231240 14% 201212 20% 12%13% 13%1797%191196 12% 200 158 3% 8% 8%126130131134138 8% 8% 1011097%117 7% 6% 72 84 5%4%5% 5% 5% 4% 5% 5% 4% 4% 4%5% 4% 57 64 3% 2%3% 3% 4% 2% 3% 4% 2% 2% 2% 3%3%2% 2%3% 2% 4% 3%3%2%2%2%3%2% 2% 3% 2% 24 280%280%28 1% 1% 0% 1%0% 0%0% 2%2% 0% 0% 2%0% 1% 1% 2%2% 2% 0 0% 1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr 1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may 01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun 10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar 10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may # of cases % increase Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ June 2020 Confidential Hovione © 2020 17 Coronavirus (SARS-CoV-2 / COVID 19) – Lisbon - Confirmed cases by day 250 228 200 150 97 97 100 82 85 75 71 60 60 55 54 54 56 48 48 48 48 50 51 39 41 40 41 41 39 41 353839 40 38 50 34 34 32 36 3634 27 31 283031 31 26 20 1924 23 24 22 24 24 2024 1924 24 19 19 18 16 15 16 13 18 14 12 7 12 11 9 0 5 5 0 0 0 2 5 0 1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr 1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may 01.jun 02.jun 03.jun 04.jun
Load more

Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000
    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
    [Show full text]
  • Interim Recommendations for Use of the Moderna Mrna-1273 Vaccine Against COVID-19
    Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 Interim guidance First issued 25 January 2021 Updated 15 June 2021 Background This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021 (1) and updated during its extraordinary meeting on 27 May 2021(2). Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence summarised in the Background document on the Moderna mRNA-1273 vaccine against COVID-19 (3) and the background paper on COVID-19 disease and vaccines (4). Annexes which include GRADE and evidence-to-recommendations (ETR) tables have also been updated to reflect the updated recommendations. All referenced documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic- advisory-group-of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the mRNA-1273 vaccine, manufactured by Moderna. The vaccine is also known as COVID-19 Vaccine Moderna. In the subsequent text the vaccine will be referred to as mRNA-1273. On 30 April 2021, mRNA-1273 was granted WHO’s Emergency Use Listing (EUL). Methods SAGE applies the principles of evidence-based medicine and has set in place a thorough methodological process for issuing and updating recommendations (5). A detailed description of the methodological processes as they apply to COVID-19 vaccines can be found in the SAGE evidence framework for COVID-19 vaccines (6).
    [Show full text]
  • Moderna Vaccine Day Presentation
    Zika Encoded VLP mRNA(s) RSV CMV + EBV SARS-CoV- RSV-ped 2 Flu hMPV/PIV3 H7N9 Encoded mRNA(s) Ribosome Protein chain(s) First Vaccines Day April 14, 2020 © 2020 M oderna Therapeutics Forward-looking statements and disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning; the impact of the SARS-CoV-2 pandemic on the Company’s clinical trials and operations; the timing and finalization of a dose-confirmation Phase 2 study and planning for a pivotal Phase 3 study for mRNA-1647; the status and outcome of the Phase 1 clinical trial for mRNA-1273 being conducted by NIH; the next steps and ultimate commercial plan for mRNA-1273; the size of the potential market opportunity for mRNA-1273; the size of the potential commercial market for novel vaccines produced by Moderna or others; the potential peak sales for the Company’s wholly-owned vaccines; the probability of success of the Company’s vaccines individually and as a portfolio; and the ability of the Company to accelerate the research and development timeline for any individual product or the platform as a whole. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
    [Show full text]
  • The Covid–19 Pandemic and Haemoglobin Disorders
    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
    [Show full text]
  • Biopharma R&D on Treatment and Vaccines
    Biopharma R&D on Treatment and Vaccines Coronavirus: Gilead Readies For Remdesivir Ramp Up, Questions On Profit Motive Demand Could Be High For Antiviral Executive Summary “All of that is at risk in not knowing if the drug If clinical trials prove it effective against COVID-19, works or not – and that is really not with an eye to remdesivir could potentially help millions of commercial,” she added. patients - which raises big questions about funding and access. Mercier said the company was spending more time on considering issues of access to the drug once its safety and efficacy is established – especially in regions of the world with less As vaccines will take around 12 months to developed healthcare systems. develop, companies with antiviral treatments are now been pushed to the front line in the battle Nevertheless, Gilead is contemplating a possible against coronavirus, and Gilead Sciences Inc.’s commercial future for the drug. remdesivir is currently the biggest hope of a drug to treat infected patients. “I have to be honest, commercial opportunity might come if this becomes a seasonal disease The company had big news to talk about on 2 or if stockpiling comes into play, but that is much March at the Cowen Health Care conference, as it later down the line,” concluded Mercier. had announced earlier in the day the acquisition of oncology firm Forty Seven for $4.9bn. (Also see One precedent for a big commercial hit for an “Gilead Calls Forty Seven Buyout Complementary antiviral product is Roche’s Tamiflu (oseltamivir). To Kite, Other IO Efforts” - Scrip, 2 Mar, 2020.) The drug achieved peak revenues of $3bn in 2009, largely down to stockpiling in response to that Speaking at the investor conference, Gilead’s chief year’s H1N1 flu pandemic.
    [Show full text]
  • Effectiveness of Pfizer-Biontech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    Morbidity and Mortality Weekly Report Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 Mark W. Tenforde, MD, PhD1; Samantha M. Olson, MPH1; Wesley H. Self, MD2; H. Keipp Talbot, MD2; Christopher J. Lindsell, PhD2; Jay S. Steingrub, MD3; Nathan I. Shapiro, MD4; Adit A. Ginde, MD5; David J. Douin, MD5; Matthew E. Prekker, MD6; Samuel M. Brown, MD7; Ithan D. Peltan, MD7; Michelle N. Gong, MD8; Amira Mohamed, MD8; Akram Khan, MD9; Matthew C. Exline, MD10; D. Clark Files, MD11; Kevin W. Gibbs, MD11; William B. Stubblefield, MD2; Jonathan D. Casey, MD2; Todd W. Rice, MD2; Carlos G. Grijalva, MD2; David N. Hager, MD, PhD12; Arber Shehu, MD12; Nida Qadir, MD13; Steven Y. Chang, MD, PhD13; Jennifer G. Wilson, MD14; Manjusha Gaglani, MBBS15,16; Kempapura Murthy, MPH15; Nicole Calhoun, LMSW, MPA15; Arnold S. Monto, MD17; Emily T. Martin, PhD17; Anurag Malani, MD18; Richard K. Zimmerman, MD19; Fernanda P. Silveira, MD19; Donald B. Middleton, MD19; Yuwei Zhu, MD2; Dayna Wyatt2; Meagan Stephenson, MPH1; Adrienne Baughman2; Kelsey N. Womack, PhD2; Kimberly W. Hart2; Miwako Kobayashi, MD1; Jennifer R. Verani, MD1; Manish M. Patel, MD1; IVY Network; HAIVEN Investigators On April 28, 2021, this report was posted as an MMWR Early ≥65 years. Vaccination is a critical tool for reducing severe Release on the MMWR website (https://www.cdc.gov/mmwr). COVID-19 in groups at high risk. Adults aged ≥65 years are at increased risk for severe outcomes Randomized clinical trials of vaccines that have received an from COVID-19 and were identified as a priority group to EUA in the United States showed efficacy of 94%–95% in receive the first COVID-19 vaccines approved for use under preventing COVID-19–associated illness (4,5).§ However, an Emergency Use Authorization (EUA) in the United States hospitalization is a rare outcome among patients with (1–3).
    [Show full text]
  • Comparing Three Covid-19 Vaccines: Pfizer, Moderna, J&J
    Comparing three Covid-19 vaccines: Pfizer, Moderna, J&J 3/1/21, 2:09 PM Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson By Helen Branswell Feb. 2, 2021 CVS registered pharmacist Ken Ramey prepares to give a Covid-19 vaccine at the Isles of Vero Beach assisted and independent senior living community in Vero Beach, Fla. Wilfredo Lee/AP In an ideal world, a pandemic vaccine could be delivered in a single shot, so supplies could be stretched to cover a lot of people. It would trigger no side effect more significant than a sore arm. And it would be easy to ship and store. https://www.statnews.com/2021/02/02/comparing-the-covid-19-vaccines-developed-by-pfizer-moderna-and-johnson-johnson/ Page 1 of 10 Comparing three Covid-19 vaccines: Pfizer, Moderna, J&J 3/1/21, 2:09 PM We now have one such vaccine. On Feb. 27, the Food and Drug Administration announced it had issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine. Developed by J&J’s vaccines division, Janssen Pharmaceuticals, it was shown to be 66% protective against moderate to severe Covid infection in a multi-country study. Importantly, it was 85% effective in protecting against severe disease. And there were no hospitalizations or deaths among people in the vaccine arm of a large clinical trial. Overall efficacy varied a bit geographically, especially in South Africa, where a new variant appears to evade to some degree the immunity induced both by infection and by Covid vaccines, which were designed to target earlier strains of the SARS-CoV-2 virus.
    [Show full text]
  • Biopharma Leaders Unite to Stand with Science
    Biopharma Leaders Unite to Stand with Science • Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines NEW YORK, September 8, 2020 (GLOBE NEWSWIRE) – The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech SE (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles. The safety and efficacy of vaccines, including any potential vaccine for COVID-19, is reviewed and determined by expert regulatory agencies around the world, such as the United States Food and Drug Administration (FDA). FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US. FDA’s guidance and criteria are based on the scientific and medical principles necessary to clearly demonstrate the safety and efficacy of potential COVID-19 vaccines. More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer- blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations.
    [Show full text]
  • David Meline Joins Moderna As Chief Financial Officer
    David Meline Joins Moderna as Chief Financial Officer June 4, 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that David Meline has joined Moderna as Chief Financial Officer, effective Monday, June 8, 2020. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel. “I am pleased to welcome David to Moderna as our Chief Financial Officer and to the Executive Committee. As we prepare for the Phase 3 studies of our SARS-CoV-2 vaccine and our CMV vaccine, we are entering another critical phase for the Company. We have started to build commercial capabilities and started to set up commercial subsidiaries in several countries,” said Stéphane Bancel, Chief Executive Officer of Moderna. “David’s global biopharmaceutical industry and commercial experience along with his track record as CFO of Amgen for the last 6 years and before that, as CFO of 3M, make him a great addition to our team. I look forward to partnering with David to grow Moderna to a global enterprise focused on development and delivery of novel therapeutics and vaccines.” Mr. Meline joins Moderna from Amgen (Nasdaq: AMGN), where he served as Chief Financial Officer and EVP from 2014 through 2019. At Amgen, he was responsible for all finance, information systems and global business services activities across 100 countries. In this role, Mr. Meline led enterprise-wide transformation while increasing growth and productivity and reducing development cycle time.
    [Show full text]
  • Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older
    Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older Purpose Inform recipients, especially males 12 through 29 years of age To reduce morbidity and mortality from coronavirus disease and their parents/legal representative (when relevant) of the 2019 (COVID-19) by vaccinating persons who meet the criteria possibility of myocarditis or pericarditis following receipt of mRNA COVID-19 vaccines and the need to seek care if symptoms of established by the Centers for Disease Control and Prevention’s ‡ Advisory Committee on Immunization Practices (ACIP). myocarditis or pericarditis develop after vaccination. For people who received a COVID-19 vaccine that is not Policy currently authorized in the United States, guidance can be Where authorized under state law, standing orders enable found at: https://www.cdc.gov/vaccines/covid-19/info-by- eligible nurses and other healthcare professionals (e.g., product/clinical-considerations.html#not-authorized-vaccines pharmacists) to assess and vaccinate persons who meet the Moderna COVID-19 vaccine may be coadministered with criteria in the "Procedure" section below without the need other vaccines - on the same day, as well as within 14 days of for clinician examination or direct order from the attending each other.§ provider at the time of the interaction. For recommendations for COVID-19 vaccination and Procedure SARS-CoV-2 infection, see https://www.cdc.gov/vaccines/ covid-19/clinical-considerations/covid-19-vaccines-us. Assess persons 18 years of age and older for vaccination with html#CoV-19-vaccination Moderna COVID-19 Vaccine based on the following criteria: Screen for contraindications and precautions.
    [Show full text]
  • Event Study: the Influence of COVID-19 Research and Development
    Event Study: The Influence Of COVID-19 Research and Development News on Pharmaceutical and Biotech Companies Lydia Chuyue Zhang1 College of Literature, Science, and the Arts University of Michigan – Ann Arbor [email protected] April 9, 2021 1 I thank Professor Pablo Ottonello, Professor Kathryn Dominguez, and Professor Linda Tesar for their helpful comments. Zhang 2 Abstract This event study estimates the influence of COVID-19 related research and development news on pharmaceutical and biotech companies and its impact on the stock market. Results show that companies can grow 4% to 63.92% from their development progress, except for Johnson & Johnson’s -2.96% loss on January 29th, 2021. Dynamics between vaccine and treatment drug developers were collaborative initially and more competitive later. The market prefers certain firms such as Moderna, CureVac, and Gilead, who are less likely to be defeated by others’ success and more likely to disrupt others with their progress. Private and public benefits from vaccine and drug developments mostly align, except when Novavax’s and Johnson & Johnson’s positive announcements collided. Lastly, positive market sentiment seems to influence small-cap and mid- cap firms more than large-caps, while negative events have less impact on them. Zhang 3 Ⅰ. Introduction This event study estimates the influence of COVID-19 related research and development news on pharmaceutical and biotech companies and its impact on the stock market. During COVID-19, the healthcare sector is attracting significant investments from governments and investors. The pandemic outbreak severely damaged the U.S economy and stock market during March 2020, which exacerbated domestic and external political conflicts.
    [Show full text]
  • Moderna COVID-19 Vaccine Storage and Handling Summary
    Moderna COVID-19 Vaccine Storage and Handling Summary Basics Store vaccine in a freezer or refrigerator. See guidance below for each storage unit. Use vaccine vials stored in the refrigerator before removing vials from frozen storage. Check and record storage unit temperature each workday. See guidance below for each type of temperature monitoring device. Save storage records for 3 years, unless your jurisdiction requires a longer time period. Deliveries Vaccine 1. The vaccine will arrive frozen between -50°C and -15°C (-58°F and 5°F). 2. Examine the shipment for signs of damage. 3. Open the box and remove TagAlert Temperature Monitor from box (placed in the inner box next to vaccine). 4. Check the TagAlert temperature monitoring device by pressing the blue “start and stop” button. Left arrow points to a green checkmark: The vaccine is ready to use. Store the vaccine at proper temperatures immediately. Right arrow points to a red X: The numbers 1 and/or 2 will appear in the display. Store the vaccine at proper temperatures and label DO NOT USE! Call the phone number indicated in the instructions or your jurisdiction's immunization program IMMEDIATELY! 5. The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date: Scan the QR code located on the outer carton, or Go to www.modernatx.com/covid19vaccine-eua/. Ancillary Supply Kit An ancillary kit with supplies will be provided for administering the vaccine. Administration supplies include needles, syringes, sterile alcohol prep pads, vaccination record cards (shot cards), and some PPE.
    [Show full text]